Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 20;23(3):1104.
doi: 10.3390/ijms23031104.

Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity

Yasunori Omata  1   2 , Michael Frech  3   4 , Taku Saito  1 , Georg Schett  3   4 , Mario M Zaiss  3   4 , Sakae Tanaka  1
Affiliations
Review

Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity

Yasunori Omata et al. Int J Mol Sci. .

Abstract

While type 2 immunity has traditionally been associated with the control of parasitic infections and allergic reactions, increasing evidence suggests that type 2 immunity exerts regulatory functions on inflammatory diseases such as arthritis, and also on bone homeostasis. This review summarizes the current evidence of the regulatory role of type 2 immunity in arthritis and bone. Key type 2 cytokines, like interleukin (IL)-4 and IL-13, but also others such as IL-5, IL-9, IL-25, and IL-33, exert regulatory properties on arthritis, dampening inflammation and inducing resolution of joint swelling. Furthermore, these cytokines share anti-osteoclastogenic properties and thereby reduce bone resorption and protect bone. Cellular effectors of this action are both T cells (i.e., Th2 and Th9 cells), but also non-T cells, like type 2 innate lymphoid cells (ILC2). Key regulatory actions mediated by type 2 cytokines and immune cells on both inflammation as well as bone homeostasis are discussed.

Keywords: osteoclast; rheumatoid arthritis; type 2 immunity; type 2 innate lymphoid cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Regulation of inflammation and bone metabolism by type 2 immunity. In an inflammatory status of RA, ILC2s, Th2 cells, and eosinophils exert anti-inflammatory properties in the inflamed joint by producing type 2 cytokines such as IL-4 and IL-13. Type 2 cytokines suppress the production of inflammatory cytokines by macrophages. Activated macrophages secrete proinflammatory cytokines IL-1 and TNFα, which stimulate synovial fibroblasts to express RANKL. Type 2 immunity can modulate bone metabolism by regulating the secretion of inflammatory cytokines. In the bone marrow environment, osteoclasts and osteoblasts regulate bone metabolism. IL-4 and IL-13, which are secreted by type 2 immune cells, control osteoclast differentiation directly and indirectly.
Figure 2
Figure 2
Type 2 immunity and cytokine production. Th2 cells, ILC2s, eosinophils, mast cells, basophils, and Th9 cells are type 2 immune cells producing IL-4, IL-5, IL-9, and IL-13.
Figure 3
Figure 3
Type 2 immunity and arthritis. Naive T cells differentiate into Th2 cells by the activation of GATA3 genes. Th2 cells and ILC2s produce IL-4 and IL-13, which suppress macrophage activation in the inflammatory status. Th2 cells and ILC2s also secrete IL-5, activating eosinophils to generate IL-4 and IL-13. Naive T cell-derived Th2 and Th9 can produce IL-9. IL-9 enhances the interaction of ILC2s and Tregs to alleviate inflammation. ILC2s regulate both the initiation and resolution of arthritis.
Figure 4
Figure 4
Type 2 immunity and bone homeostasis. Th2 cells and ILC2s generate IL-4, IL-5, and IL-13. IL-5 activates eosinophil, and it secretes IL-4 and IL-13. Type 2 cytokines suppress the differentiation of osteoclasts by regulating the expression of STAT6. Type 2 cytokines stimulate osteoblasts to generate OPG, which inhibits osteoclastogenesis.
See this image and copyright information in PMC

References

    1. Wynn T.A. Type 2 cytokines: Mechanisms and therapeutic strategies. Nat. Rev. Immunol. 2015;15:271–282. doi: 10.1038/nri3831. - DOI - PubMed
    1. Komatsu N., Takayanagi H. Inflammation and bone destruction in arthritis: Synergistic activity of immune and mesenchymal cells in joints. Front. Immunol. 2012;3:77. doi: 10.3389/fimmu.2012.00077. - DOI - PMC - PubMed
    1. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheumatol. 2000;43:259–269. doi: 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W. - DOI - PubMed
    1. Moser M., Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 2000;1:199–205. doi: 10.1038/79734. - DOI - PubMed
    1. Amsen D., Blander J.M., Lee G.R., Tanigaki K., Honjo T., Flavell R.A. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell. 2004;117:515–526. doi: 10.1016/S0092-8674(04)00451-9. - DOI - PubMed